News & Events
Press releases, media coverage, and where to find us at conferences. For peer-reviewed methodology, see Publications.
Press release · Oct 23, 2026
Pentara to present rare disease statistical innovations at NORD Summit aligning with FDA's new framework initiative
SALT LAKE CITY, UT, October 23, 2026. Pentara Corporation, an independent biostatistics and regulatory consulting firm, will present research on recovering statistical power in small rare disease trials at the NORD® Rare Diseases & Orphan Products Breakthrough Summit®, October 25–27 in Washington, D.C. The presentation follows the U.S. Food and Drug Administration's launch of its Rare Disease Framework Initiative, which aims to align regulatory expectations with the evidence that small patient populations can realistically generate.
Press releases and coverage
Newest first
-
Jul 09, 2026
Read →Pentara to present five original Alzheimer's research studies at AAIC 2026
Announcement of the company's AAIC program, covering anti-amyloid durability, biomarker selection, trial representation, and study design, with a CEO comment on statistical work that shortens the path from trial to patient.
-
Jan 07, 2026
Read →Science cites Pentara analysis in reporting on clinical trial data integrity
Suzanne Hendrix discusses proprietary analyses that flagged sites enrolling participants unlikely to have Alzheimer's disease, and cases of a single blood sample submitted for several participants, the kind of signal our data quality protection work is built to surface.
-
Jul 30, 2025
Read →NetraMark and Pentara partner on AI-driven detection of anomalous site and participant behavior
A co-branded site intelligence tool combining information-theoretic variability, singleton occurrence frequencies, and co-association penalties into a participant-level Paradox Risk score for assessing site-level trial integrity.
-
Apr 02, 2025
Read →NeurologyLive covers Pentara-led analysis of pTau217 and pTau181 against trial endpoints
Reporting on AD/PD 2025 work led by Craig Mallinckrodt, Ph.D., examining patient-level and group-level correlations between plasma biomarkers and clinical outcomes across the ENGAGE, EMERGE, TRAILBLAZER, and Clarity AD trials.
Conference abstracts, posters, and journal papers are listed on Publications.